FDA Approves Zynrelef For Managing Postoperative Pain Up To
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The US Food and Drug Administration (FDA) has given its approval to Heron Therapeutics' Zynrelef (bupivacaine and meloxicam) for the treatment of postoperative pain for up to 72 hours. With the approval, Zynrelef becomes the first and only FDA-approved extended-release dual-acting local anesthetic, clinically proven to manage pain and to eliminate the need for opioids for up to 72 hours following surgery.

Zynrelef delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal antiinflammatory drug (NSAID) meloxicam. The synergy between bupivacaine and meloxicam in Zynrelef has resulted in patients experiencing significantly less pain, including severe pain, and significantly more patients requiring no opioids (opioid-free) after surgery as compared to the current standard-of-care bupivacaine solution.

"The approval of ZYNRELEF marks an exciting milestone for patients, healthcare providers and pain management. Not just because it can reduce postoperative pain for up to 72 hours, but because for many patients it can eliminate the need for opioids after surgery," Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron said in a statement.

The approval was based on results from multiple double-blind, placebo- and active-controlled phase 3 and phase 2 studies involving over 1000 patients. The trial showed that:

· Among patients undergoing unilateral simple bunionectomy (N=412), treatment with Zynrelef was associated with a significant reduction in pain intensity compared with either bupivacaine HCl or saline placebo for up to 72 hours.

· A significant proportion of patients in the Zynrelef arm did not receive opioid analgesia (29% vs 11% for bupivacaine HCl and 2% for saline placebo).

· Similar results were observed in a study involving 418 patients undergoing unilateral open inguinal herniorrhaphy.

· Zynrelef also showed a significant reduction in pain intensity vs saline placebo for the first 48-hour and 72-hour postoperative periods in patient who underwent primary unilateral total knee arthroplasty (N=222).

· This study also included a group of patients treated with Zynrelef plus ropivacaine, as well as those who received bupivacaine only.

· Both Zynrelef treatment groups demonstrated a reduction in pain intensity compared with the bupivacaine arm.

Source:
https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-us-fda-approval-zynreleftm-htx-011
Dr. C●●●●g R●●●●●i and 2 other likes this1 share
Like
Comment
Share